Increasing number of ATPM clinical trials in the UK

In contrast to overall UK pharma industry claims of falling R&D in the country, the Cell and Gene Therapy Catapult (CGT Catapult) reports the opposite.

The organization today published its 11th annual UK Advanced Therapy Medicinal Products (ATMP) Clinical Trials Report, which covers ATMP clinical trial activities which the CGT Catapult understands to be ongoing in the UK in 2022. Updated annually, the 2022 report shows that clinical trials in the UK ATMP sector continued to perform consistently in the last year.

Earlier this week, Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI), in the context of the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), said: “We have already seen the UK lose almost half of its global share of R&D over the last decade.”